What is the efficacy and safety of febuxostat in lowering hyperuricemia in patients aged 65 years or older?

Updated: Jan 26, 2021
  • Author: Bruce M Rothschild, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

In patients aged 65 years or older, the primary endpoint was achieved in 62% on febuxostat 40 mg/day, 82% on febuxostat 80 mg/day, and 47% on allopurinol. These figures remained essentially unchanged in subjects with mild-to-moderate renal impairment. [170]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!